Published in Cancer Weekly, November 27th, 2001
Cyclacel's CYC102 program is seeking to prevent cancer cell proliferation through drugs acting on PCNA. The CYC102 studies are based on the understanding that inhibition of PCNA prevents DNA replication, a prerequisite to cancer cell division. Cyclacel is working on this target because it is associated with the body's own tumour suppression systems, such as the p21 protein that prevents cancer cell division by inhibiting PCNA.
Cyclacel's new U.S. patent specifically covers both substances that mimic the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.